Table 2.
Transplant outcomes for B-ALL patients who underwent allo-SCT in different sub-group cases.
| Parameters | n | 5-year relapse | 5-year OS | 5-year LFS | 5-year NRM |
| Total patients | 477 | 20.7 (17.0–24.4) | 70.4 (66.3–74.5) | 65.6 (61.3–69.9) | 13.9 (10.8–17.0) |
| Pre-MRD | |||||
| Negative | 359 | 15.5 (12.3–18.7)∗ | 73.3 (68.6–78.0)∗ | 69.0 (64.1–73.9)∗ | 16.1 (12.1–20.1) |
| Positive | 118 | 36.4 (27.7–45.1) | 61.8 (53.0–70.6) | 55.3 (46.1–64.5) | 7.6 (2.8–12.4) |
| Post-MRD | |||||
| Negative | 400 | 11.9 (8.7–15.1)† | 76.0 (71.7–80.3)† | 72.8 (68.3–77.3)† | 15.5 (11.9–19.1) |
| Positive | 77 | 66.6 (61.1–72.1) | 41.5 (52.5–30.5) | 28.2 (17.6–38.8) | 5.2 (0.2–10.2) |
| Risk score system | |||||
| 0 | 159 | 6.3 (2.6–10.0)‡ | 85.7 (80.0–91.4)‡ | 83.2 (77.1–89.3)‡ | 10.6 (5.5–15.7) |
| 1 | 235 | 16.6 (11.7–21.5)‡ | 69.2 (62.7–75.7)‡ | 66.6 (60.5–72.7)‡ | 17.1 (12.2–22.0) |
| 2 | 72 | 55.9 (43.9–67.5) | 36.6 (24.8–48.4) | 31.8 (20.8–42.8) | 12.3 (4.7–19.9) |
| 3 | 11 | 81.8 (55.3–100.0) | 27.3 (1.0–53.6) | 18.2 (0–40.9) | 0 |
Data are presented as percentage of incidence (95% confidence interval).
∗
Indicates P < 0.05 compared with patients with pre-MRD positive.
†
Indicates P < 0.05 compared with patients with pre-MRD positive.
‡
Indicates P < 0.05 compared with patients with the other three risk scores. allo-SCT: Allogeneic stem cell transplantation; B-ALL: B cell acute lymphocytic leukemia; CI: Confidence interval; HR: Hazard ratio; LFS: Leukemia-free survival; MRD: Minimal residual disease; NRM: Non-relapse mortality; OS: Overall survival.